According to the American Heart Association, more than 13 million people suffer from coronary heart disease, 6 million from angina, and 7 million from myocardial infraction. Rapid technological advances and product innovation are transforming the cardiology market.
Vivostat is a Danish company that uses the patient’s blood to create a personalized surgical glue (fibrin sealant) that can be used for surgical procedures and the treatment of diabetic ulcers.
CVT’s system, currently under development, is the first self-conforming and self-anchoring technology for transcatheter mitral valve implantation (TVMI).
REPEL-CV, an anti-adhesion barrier developed by biomaterials company SyntheMed, has received approval by the Australian Therapeutic Goods Administration for use in open-heart surgery.
Copyright © 2025 | WordPress Theme by MH Themes